Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | PPID | Q08752 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 4/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 3/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30909992 | 0.89 | SCN8A (0.51) | SCN8ALTA4HERCC1ERCC4VNN1 | |
| SCHEMBL6163414 | 0.83 | LOXL2 (0.49) | SCN8APPIDLTA4HSMN1; SMN2 | |
| SCHEMBL29860036 | 0.83 | SCN8A (0.47) | SCN8AERCC1ERCC4VNN1DPP7 | |
| SCHEMBL5725267 | 0.82 | PDCD1 (0.54) | PDCD1CD274ERCC1ERCC4MEP1A | |
| SCHEMBL30088453 | 0.82 | PDCD1 (0.54) | PDCD1CD274ERCC1ERCC4MEP1A | |
| SCHEMBL11954384 | 0.82 | KMT2A (0.53) | PPIDLTA4HSMN1; SMN2 | |
| Benzonitrile SCHEMBL9811793 | 0.80 | SMN1; SMN2 (0.53) | PDCD1CD274PPIDLTA4HPOLB | |
| SCHEMBL2774523 | 0.80 | FFAR1 (0.52) | SCN8APDCD1CD274ERCC1ERCC4 | |
| SCHEMBL6881434 | 0.80 | FFAR1 (0.52) | PDCD1CD274FFAR1CNR2POLB | |
| SCHEMBL23703051 | 0.80 | CYP1A2 (0.50) | PPIDLTA4HSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110091-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11110091-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| CN-108290893-B | Dihydroperidinone derivatives, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20190321366-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2019-10-24 | — | — | US | disclosed |
| US-20190321366-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10172860-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172860-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| CN-108290893-A | Dihydroperidinone derivatives, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2018-07-17 | — | — | CN | disclosed |
| US-20180085370-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085370-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20130071354-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8367670-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367670-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367670-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2364314-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | Gilead Sciences, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010077613-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077613-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085370-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | SCN8A 2877/4885PDCD1 3840/4885CD274 2219/4885 |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | SCN8A 2877/4885PDCD1 3840/4885CD274 2219/4885 |
| US-10172860-B2 | Modulators of toll-like receptors | TLR3, TLR2, TLR6 | SCN8A 2877/4885PDCD1 3840/4885CD274 2219/4885 |
| US-11110091-B2 | Modulators of toll-like receptors | TLR3, TLR2, TLR6 | SCN8A 2877/4885PDCD1 3840/4885CD274 2219/4885 |
| US-20190321366-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | SCN8A 2877/4885PDCD1 3840/4885CD274 2219/4885 |
| US-20130071354-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | SCN8A 2877/4885PDCD1 3840/4885CD274 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.